Related Experiment Videos
Metoprolol in portal hypertension. A controlled study
Klinische Wochenschrift
|October 15, 1982
Summary
Metoprolol effectively reduced portal hypertension in 60% of patients with liver cirrhosis. This beta-blocker may offer a valuable treatment option, but repeated pressure measurements are needed to identify non-responders.
Area of Science:
- Hepatology
- Cardiovascular Pharmacology
Background:
- Portal hypertension is a serious complication of liver cirrhosis.
- Effective management strategies for cirrhotic portal hypertension are crucial.
Purpose of the Study:
- To investigate the efficacy of metoprolol, a beta 1-selective blocking agent, in treating cirrhotic portal hypertension.
- To assess the impact of metoprolol on portal pressure and its correlation with cardiac output.
Main Methods:
- A controlled trial was conducted to evaluate metoprolol's effect.
- Portal pressure and cardiac output were monitored in patients with liver cirrhosis.
Main Results:
- A sustained reduction in portal pressure was observed in 60% of patients treated with metoprolol after 1 and 2 months.
- No significant correlation was found between changes in portal pressure and cardiac output.
- Findings suggest a potential direct action of beta-blockers on the splanchnic vascular system.
Conclusions:
- Metoprolol may be a beneficial treatment for portal hypertension secondary to liver cirrhosis.
- Repeated portal pressure measurements are recommended to identify non-responders and optimize treatment.